Americord Funds Clinical Trial Examining the Use of Donor Stem Cells in Patients with Previously Treated Cancers

NEW YORK, Dec. 16, 2014 /PRNewswire/ -- Americord Registry announced today that it has provided funding to the Masonic Cancer Center at the University of Minnesota. Funding will support research into the possible use of donor stem cells in patients with previously treated lymphoma, myeloma, or chronic lymphocytic leukemia. All three are cancers of the blood or bone marrow.

Logo - http://photos.prnewswire.com/prnh/20141215/164511LOGO

Researchers are interested in using donor stem cells to further treat patients who have previously received chemotherapy. The use of chemotherapy, such as cyclophosphamide and busulfan, helps stop the growth of cancer cells. In addition, chemo stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells from bone marrow or umbilical cord blood may be able to replace the patient's immune cells and help destroy any remaining cancer cells.

Americord's donation of funds is part of the company's Corporate Giving Program, which was established to support research focused on the therapeutic uses of stem cells from umbilical cord blood, cord tissue, and placenta tissue.

"Americord is committed to supporting the advancement of stem cell treatments and technologies," said Americord CEO Martin Smithmyer. "We are excited about the research being done at the Masonic Cancer Center and the potential it has for future treatment options."

The study at the Masonic Cancer Center began in February 2008 and is anticipated to be complete by January 2015. It is registered with ClinicalTrials.gov in accordance with best practices and requirements of the U.S. Food and Drug Administration.

For more information about the clinical trial, visit: https://clinicaltrials.gov/ct2/show/study/NCT00612716

About Americord Registry

Americord Registry is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord Registry's website at http://www.americordblood.com for more information.

PRESS CONTACT:
Raechel Sherwood
[email protected]
866-503-6005

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/americord-funds-clinical-trial-examining-the-use-of-donor-stem-cells-in-patients-with-previously-treated-cancers-300010290.html

SOURCE Americord Registry

Related Links

http://www.americordblood.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED